| Literature DB >> 35342008 |
Khairul Omar1, Dhesi Baha Raja1, Nur Asheila Abdul Taib2, Nadia Rajaram1, Jinat Ahmed1, H S Arvinder-Singh3, Siti Aisah Mokhtar4, Alvin Kuo Jing Teo5, Lidwina Edwin Amir1, Michelle Chan1, Yee Theng Quek1, Choo-Yee Ting6.
Abstract
BACKGROUND: Guided by the best practices adapted from national and international bodies including the World Health Organization (WHO), the Centers for Disease Control (CDC), and the UK Joint Biosecurity Centre (JBC), this paper aims to develop and provide an empirical risk stratification and assessment framework for advancing the safe resumption of global travel during the COVID-19 pandemic.Entities:
Keywords: COVID-19; Country risk stratification; International travel reopening; Malaysia; SARS-CoV-2; Weighted score
Mesh:
Year: 2022 PMID: 35342008 PMCID: PMC8949657 DOI: 10.1016/j.tmaid.2022.102318
Source DB: PubMed Journal: Travel Med Infect Dis ISSN: 1477-8939 Impact factor: 20.441
Parameters included in our risk assessment framework and their corresponding definitions, with comparisons to the indicators used in the frameworks employed by WHO, CDC, and JBC.
| Pillar | Parameter | Definition | WHO [ | CDC [ | JBC [ |
|---|---|---|---|---|---|
| (1) | Cases per million population, 7-day average | New cases divided by population x 1 million, averaged over 7 days. | |||
| Change in cases vs. cases in the preceding 14 days | Difference between cases per 1 million population (7-day average) on latest date and cases per 1 million population (7-day average) as of 14 days ago. Categorization format: 0 = Decreasing, 1 = Increasing at low rate (below 100), 2 = Increasing at high rate (above 100). | ||||
| (2) | Test positivity rate, | New cases divided by total daily tests conducted, averaged over 7 days [ | |||
| Tests per 100 population, | Number of tests done per 100 population | ||||
| Trust in COVID-19 information from government (%) | Percentage of UMD Global CTIS survey respondents who declared their trust in COVID-19 information that came from government health departments [ | ||||
| (3) | Vaccinated population (%) | Percentage of total population that have completed full course of COVID-19 vaccination as prescribed by the protocol. | |||
| Case fatality rate, | Ratio between the 7-day average of deaths and the 7-day average of cases 10 days earlier. | ||||
| (4) | Genome sequencing capability | Number of sequencing samples uploaded to GISAID over the past 2 weeks divided by total number of cases over 2 weeks prior to upload date x 100. Categorization format: 0 = Excellent (more than 1%), 1 = Moderate (less than 0.1%), 2 = None (no sequencing) | |||
| Genome sequencing reporting delay | Categorization is based on the number of days since the last genomic sequencing data uploaded to GISAID [ | ||||
| Presence of very high priority variant of concern | Flags if a very high priority variant of concern is detected. Categorization format: 0 = Not present, 1 = Present. |
Note: Definitions shown in Table 1 reflect the objectives of this paper and may not necessarily match the exact definitions used by WHO, CDC and JBC.
Fig. 1aIntra-pillar risk assessment score calculation flowchart.
Fig. 1bInter-pillar risk assessment score calculation flowchart.
Weightage used in the model for intra-pillar and inter-pillar calculations.
| COVID-19 variable | Intra-pillar weight | Pillar | Inter-pillar weight |
|---|---|---|---|
| Cases per million population, 7-day average | (1) | ||
| Change in cases per million population vs. preceding 14 days | |||
| Test positivity rate, 7-day average | |||
| Tests per 100 population, 7-day average | (2) | ||
| Trust in COVID-19 information from the government % | |||
| Vaccinated population % | (3) | ||
| Case fatality rate %, 7-day average | |||
| Genome sequencing capability | (4) | ||
| Genome sequencing reporting delay | |||
| Presence of very high priority variant of concern |
Note: Weights shown are tailored to the situation of the pandemic situation as of October 6, 2021. As the situation continuously evolves, the weights should be adapted to the present-day priorities as outlined in the upcoming Section 4.
Sample calculation of country risk score for Australia as of October 6, 2021.
| Value | Categorized | Normalized | Weight | Weighted | ||
|---|---|---|---|---|---|---|
| Cases per million population, 7-day average | 82.6 | 0.08 | 5 | 0.38 | ||
| Change in cases per million population vs. past 14 days | 17.4 | 1 | 0.50 | 3 | 1.50 | |
| Weighted score: Incidence of cases | 1.88 | |||||
| Test positivity rate %, 7-day average | 1.10 | 0.02 | 5 | 0.11 | ||
| Test per 100 population 7-day average | 0.77 | 0.23 | 3 | 0.69 | ||
| (Mis)trust in COVID-19 info from the govt. % | 55.8 | 0.47 | 1 | 0.47 | ||
| Weighted score: Reliability of case data | 1.28 | |||||
| Population not fully vaccinated % | 52.3 | 0.52 | 5 | 2.62 | ||
| Case fatality rate %, 7-day average | 0.82 | 0.05 | 2 | 0.09 | ||
| Weighted score: Vaccination | 2.71 | |||||
| Genome sequence samples to 14-day cases ratio | 0.76 | 1 | 3 | 3.00 | ||
| Genome sequence reporting delay in days | 0.00 | 0 | 2 | 0.00 | ||
| Presence of very high priority variant of concern | 0.00 | 0 | 5 | 0.00 | ||
| Weighted score: Variants of concern | 3.00 | |||||
| Pillar 1: Incidence of cases | 1.88 | 1 | 0.23 | |||
| Pillar 2: Reliability of case data | 1.28 | 1 | 0.15 | |||
| Pillar 3: Vaccination | 2.71 | 5 | 1.94 | |||
| Pillar 4: Variant surveillance | 3.00 | 3 | 0.90 | |||
| Weighted overall score | 3.23 | |||||
| 3.23 |
Distribution of normalized risk score by percentile, by pillar and for the overall stratification as of October 6, 2021.
| Percentiles of weighted risk scores | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0% | 10% | 20% | 30% | 40% | 50% | 60% | 70% | 80% | 90% | 100% | |
| Pillar 1: Incidence of cases | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 | 0.11 | 0.19 | 0.22 | 0.36 | 1.00 |
| Pillar 2: Reliability of case data | 0.00 | 0.25 | 0.35 | 0.39 | 0.45 | 0.46 | 0.49 | 0.50 | 0.51 | 0.59 | 1.00 |
| Pillar 3: Vaccination | 0.00 | 0.24 | 0.28 | 0.38 | 0.45 | 0.52 | 0.61 | 0.67 | 0.71 | 0.73 | 1.00 |
| Pillar 4: Variant surveillance | 0.00 | 0.20 | 0.30 | 0.30 | 0.50 | 0.50 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
(a) Result of normalized pillar-level and overall risk scores as calculated by our model for top 30 countries with the strongest travel ties to Malaysia and (b) Level of country risk as designated by other foreign authorities for references as of October 6, 2021.
Fig. 2Selection of the optimal threshold value for risk stratification.
Fig. 3Risk score calculation for Australia between October 2021 and February 2022.